hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06276244 id: NM040-GUP19002 briefTitle: Trial Readiness and Endpoint Assessment in Congenital and Childhood Myotonic Dystrophy acronym: GUP19002 overallStatus: ACTIVE_NOT_RECRUITING date: 2020-07-08 date: 2024-04 date: 2024-04 date: 2024-02-23 date: 2024-02-23 name: Fondazione Serena Onlus - Centro Clinico NeMO Milano class: OTHER name: Bambino Gesù Hospital and Research Institute name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS name: IRCCS Istituto delle Scienze Neurologiche di Bologna name: IRCCS Fondazione Stella Maris name: IRCCS Istituto Neurologico Mondino, Pavia, Italy name: Azienda Ospedaliera Città della Salute e della Scienza di Torino name: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta name: Istituto Giannina Gaslini briefSummary: Children with congenital myotonic dystrophy (CDM) present at birth with respiratory insufficiency, talipes equinovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. Children with childhood onset myotonic dystrophy present with symptoms later on but soon develop behavioural difficulties and learning difficulties and are at risk for autistic features and gastrointestinal symptoms. The ability to conduct a therapeutic trial in children with CDM or ChDM is directly limited by the lack of available data regarding appropriate clinical endpoints and biomarkers. Whereas there is an active Italian collaboration recruiting adults with DM1 to study muscle and multisystem aspects in this population, there is no active network in Italy involved in the pediatric population with DM1. Though the underlying mechanism is the same in adult DM1, in CDM and ChDM there are specific challenges to the pediatric population. The aim of this project is to coordinate the Italian Child Neurologist actively involved with CDM and ChDM in a common effort of standardizing protocols and procedures to be applied in the care of these patients. Specific aims are to collect functional measures and clinical information over time to define clinically meaningful endpoints and outcome measures in preparation for international therapeutic clinical trials. This project will contribute to the ongoing international study in CDM by recruiting additional patients from all over Italy and will extend the investigations to the childhood onset forms as an additional add-on pilot study in view of potential treatment options. The investigators expect that the Italian network, with Telethon support, will provide the necessary backbone for trial readiness in the pediatric population both at the national and international levels. conditions: CDM conditions: ChDM studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Physical function measure: Physical function measure: Cognitive-behavioral and Quality of Life measure: Cognitive-behavioral and Quality of Life measure: Biomarkers measure: Biomarkers sex: ALL maximumAge: 17 Years stdAges: CHILD facility: Fondazione Serena Onlus - Centro Clinico NeMO Milano city: Milan zip: 20162 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06276231 id: SalbuEase briefTitle: Nebulized Salbutamol in Acute Renal Colic overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-03-01 date: 2026-05-01 date: 2024-02-23 date: 2024-03-19 name: Oman Medical Speciality Board class: OTHER_GOV briefSummary: A Prospective, double blinded, Randomized efficacy and safety trial of Nebulized Salbutamol in acute renal colic.
METHOD: This is a double blinded randomized clinical controlled trial. Two hundred renal colic patients presenting to the emergency department will be randomized to intervention (10 mg nebulized salbutamol) and (10 ml neublized Normal saline) case groups. Both the groups will get the standard treatment (IM diclofenac 75mg) added to the intervention. Their pain before and after intervention will be measured by Numerical Rating scale (NRS pain score). Patient and attending physician will be blinded throughout the study. The Secondry outcomes are safety, need for rescue medications and time to discharge.
OUTCOME: Decrease in pain measures by NRS pain score after Nebulized Salbutamol is given, tolerability and safety evaluation. conditions: Renal Colic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 214 type: ESTIMATED name: Salbutamol name: 0.9% Normal Saline name: Diclofenac Injection measure: Pain reduction at 60 minutes measure: Adverse Event/Side Effects measure: Need of Rescue medications measure: Pain reduction rate. measure: ED revisits sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06276218 id: PSU briefTitle: Efficacy of Self - Adjustable Clavicular Brace Versus Standard Clavicular Brace for Treatment of Mid Shaft Clavicle Fracture: A Randomized Controlled Study overallStatus: RECRUITING date: 2022-02-01 date: 2024-02-15 date: 2024-02-16 date: 2024-02-23 date: 2024-02-23 name: Prince of Songkla University class: OTHER briefSummary: A randomized control trial was conducted to compare the outcomes of conservative management for closed midshaft clavicular fractures using self-adjustable clavicular brace and standard clavicular brace. conditions: Clavicle Fracture studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 68 type: ESTIMATED name: Clavicular brace measure: DASH measure: Pain, analgesic usage, radiographic outcomes, time to union, and patient satisfaction sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prince of Songkla University status: RECRUITING city: Songkla state: Hatyai zip: 90110 country: Thailand name: Thanachai Klongsangsorn role: CONTACT phone: +66991964733 email: poom_thanachai@hotmail.com lat: 7.19882 lon: 100.5951 hasResults: False
nctId: NCT06276205 id: 1037/RC/KEMU briefTitle: Vitamin D & Levothyroxine Combination Versus Levothyroxine on Lipid Profile in Hypothyroidism acronym: ViDaLLiT overallStatus: RECRUITING date: 2024-03-01 date: 2024-09-30 date: 2024-09-30 date: 2024-02-23 date: 2024-02-23 name: King Edward Medical University class: OTHER briefSummary: The goal of this clinical trial is to study the improvement of lipid levels in hypothyroid individuals after staring treatment.
Researchers will compare them with another group receiving only levothyroxine to see how much lipids improve in them conditions: Hypothyroidism Primary conditions: Lipid Disorder conditions: Dyslipidemias studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Vitamin D name: Levothyroxin measure: Decline in Total Cholesterol measure: Decline in LDL sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: King Edward Medical University status: RECRUITING city: Lahore state: Punjab zip: 54000 country: Pakistan name: AP Endocrinology role: CONTACT phone: +923004683473 email: sidrah.lodhi@gmail.com lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06276192 id: 2023-01882-01 briefTitle: Digital Physiotherapy Treatment for Patients With Subacromial Pain Compared to Usual Physiotherapy in Primary Care acronym: diSAID overallStatus: NOT_YET_RECRUITING date: 2024-02-26 date: 2026-03-26 date: 2028-03-26 date: 2024-02-23 date: 2024-02-23 name: Region Östergötland class: OTHER name: Linkoeping University briefSummary: The goal of this clinical trial is to test a digital treatment for patients with subacromial pain using the digital Shoulder Aid (diSAID) strategy. The participants in this study will be randomly assigned to digital treatment (diSAID) or to receive the treatment that is currently available in primary care, i.e. continue according to usual practice.
- Can the diSAID improve shoulder function and reduce pain for patients with subacromial pain in primary care? conditions: Subacromial Pain Syndrome conditions: Shoulder Pain conditions: Rotator Cuff Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Non-Inferiority Randomised Controlled Trial primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Digital Physiotherapy (diSAID) name: Traditional Physiotherapy measure: Mean change in shoulder function and pain after 12 weeks using The Shoulder Pain and Disability Index (SPADI) measure: Mean change in shoulder pain intensity at rest, arm activity and at night measured by numeric rating scale (NRS) measure: Mean change in pain Self-Efficacy measure: Mean change of self-reported rating of improvement measure: Mean change of health-related quality of life measure: Patients treatment expectancies measure: Patients self-reported rating of pain sensitivity measure: Costs and cost-effectiveness direct and indirect measure: Impact on the environment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anna Petersson city: Linköping zip: SE 58191 country: Sweden name: Anna Petersson, PhD student role: CONTACT phone: +46101031053 email: anna.h.petersson@regionostergotland.se name: Teresa Holmgren, PhD role: CONTACT phone: +46101034158 email: Teresa.Holmgren@regionostergotland.se name: Hanna Björnsson Hallgren, Associate Prof role: PRINCIPAL_INVESTIGATOR name: Jenny Samuelsson, PhD role: SUB_INVESTIGATOR lat: 58.41086 lon: 15.62157 hasResults: False
nctId: NCT06276179 id: KFSIRB200-97 briefTitle: Epidural Oxycodone for Pain Management for Lower Limb Amputation overallStatus: RECRUITING date: 2024-02-24 date: 2024-08-01 date: 2024-08-01 date: 2024-02-23 date: 2024-02-28 name: Kafrelsheikh University class: OTHER briefSummary: The aim of this study is to evaluate the effect of epidural oxycodone for pain management after lower limb amputation. conditions: Epidural conditions: Oxycodone conditions: Pain conditions: Lower Limb Amputation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Oxycodone name: Bupivacaine measure: Acute postoperative pain scores measure: Time to the first request for the rescue analgesia measure: Postoperative morphine consumption measure: Incidence of phantom limb pain measure: Adverse effects sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kafrelsheikh University status: RECRUITING city: Kafr Ash Shaykh state: Kafrelsheikh zip: 33516 country: Egypt name: Gamal H Shams, MD role: CONTACT phone: 00201095927971 email: gamal.shams2@gmail.com name: Ahmed A Ghareeb, MD role: PRINCIPAL_INVESTIGATOR name: Mohamed H Osman, MD role: PRINCIPAL_INVESTIGATOR name: Heba F Dawood, MD role: PRINCIPAL_INVESTIGATOR name: Mohamed M Kotb, MD role: PRINCIPAL_INVESTIGATOR lat: 31.11174 lon: 30.93991 hasResults: False
nctId: NCT06276166 id: 72374215 briefTitle: Trajectory of Frailty and Cognitive Dysfunction in Older Adults overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-06-30 date: 2026-12-31 date: 2024-02-23 date: 2024-03-07 name: Zheng Li class: OTHER briefSummary: To explore the heterogeneity of the development trend of frailty and cognitive function of older adults. conditions: Frailty conditions: Cognitive Dysfunction conditions: Community-dwelling Older Adults studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 934 type: ESTIMATED name: No intervention measure: Frailty measure: Cognitive function measure: Health status and life style measure: Activities of daily life (ADLs) measure: Anxiety measure: Apathy measure: Perceived social support measure: Social network sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276153 id: CRGGCext briefTitle: Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer acronym: CRGGCext overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2027-02-28 date: 2029-02-28 date: 2024-02-23 date: 2024-02-28 name: RenJi Hospital class: OTHER briefSummary: The aim of the study is to establishing a standardized clinical information database for patients with malignant tumors of gallbaldder. Based on the database, real-world clinical research on the diagnosis and treatment of biliary tract tumors is about to be carried out, and a high-standard cohort research foundation is laid for precision therapy. conditions: Biliary Tract Diseases conditions: Gallbladder Cancer conditions: Gallbladder Neoplasms studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 5000 type: ESTIMATED name: no interventions measure: overall survival measure: progression-free survival sex: ALL minimumAge: 18 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276140 id: 4/23/2-4661/2-9 briefTitle: Iron-deficiency Anaemia and Its Impact on Recovery After Colorectal Cancer Surgery acronym: ID-COLO overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-01 date: 2026-01 date: 2024-02-23 date: 2024-02-28 name: Oncology Institute of Vojvodina class: OTHER_GOV name: University of Bern briefSummary: The aim of this prospective, observational cohort study is to assess the impact of iron deficiency anaemia on the incidence of perioperative complications and the quality of recovery after surgery in patients undergoing colorectal cancer surgery. The main questions the study aims to answer are:
Blood samples for laboratory analyses will be collected from each study patient admitted to the surgical ward one day prior to elective surgery and on the first postoperative day during the stay in the intensive care unit. The pre-operative laboratory analyses include a complete blood count and serum iron status parameters (iron concentration, ferritin concentration, TIBC, UIBC and TSAT). Laboratory parameters analysed on the first postoperative day include complete blood count, serum concentration of electrolytes (Na, K, Ca, Cl, Mg), serum concentration of urea and creatinine, parameters of haemostasis (aPTT, PT, INR), serum concentration of C-reactive protein and procalcitonin.
The researchers will compare the group of patients with iron deficiency anaemia, the group of patients with iron deficiency in the latent stage and the control group to determine whether patients with iron deficiency have a higher incidence of perioperative complications and impaired recovery after surgery. The researchers will investigate whether iron deficiency can be detected at an early stage, when anaemia is not yet present, by calculating various red blood cell indices. conditions: Iron Deficiencies conditions: Iron Deficiency Anaemia conditions: Postoperative Complications conditions: Colorectal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Laboratory analyses for the detection of iron deficiency anaemia measure: Overall morbidity measure: Prevalence of absolute iron deficiency, functional iron deficiency and iron deficiency anaemia in the study population measure: Red blood cell transfusion rate measure: All-cause infection rate measure: Days of antibiotic use measure: Number of different antibiotics administered measure: Length of Intensive care unit-stay measure: Length of hospital-stay measure: Intraoperative complications measure: Quality of postoperative recovery measure: Reoperation measure: Estimated total iron-deficit measure: Serum ferritin level measure: Values of different erythrocyte indices sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276127 id: MERC301123 briefTitle: Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate. acronym: BisoAF overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-06 date: 2024-02-23 date: 2024-03-05 name: Oman Medical Speciality Board class: OTHER_GOV briefSummary: INTRODUCTION: The study focuses on comparing the effectiveness of oral Bisoprolol, a beta-1 adrenergic receptor blocker, against intravenous Diltiazem, a calcium channel blocker, in treating rapid atrial fibrillation or flutter with rapid ventricular response in an emergency setting. This research aims to fill the gap in empirical evidence regarding the use of oral Bisoprolol for these conditions, potentially offering a convenient, evidence-based alternative for patient management in emergency departments where established protocols are lacking.
OUTCOME: For therapy to be considered effective, patients must achieve a ventricular rate ≤110/min or experience a drop-in ventricular rate of at least 20% at 60 minutes. conditions: Atrial Fibrillation With Rapid Ventricular Response conditions: Atrial Flutter With Rapid Ventricular Response studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: * Study Design: Double-blind, randomized controlled trial.
* Monitoring: Continuous observation of vital signs and electrocardiograms for safety. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: While the treating physician, nurse, and the patient will not be blinded to the treatment, the investigator collecting data and the statistician analysing it will remain blinded to treatment allocations. This ensures unbiased data collection and analysis. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Oral Bisoprolol name: Intravenous Diltiazem measure: Efficacy Outcome Evaluated by Achieving the Target Heart Rate Reduction measure: Safety Outcome Evaluated by the Presence of serious adverse event measure: The use of Rescue medication measure: Proportion of patients who required hospitalization measure: ED revisit measure: Number of Participants Experiencing Treatment-Related Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sultan Qaboos University Hospital city: Muscat state: Al-khod zip: 38 country: Oman name: Fatin k Al omairi, MD role: CONTACT phone: 71308058 phoneExt: +968 email: r2220@resident.omsb.org name: Awatif Al-Alalawi, MD role: PRINCIPAL_INVESTIGATOR name: Usama Alkhalasi, MD role: SUB_INVESTIGATOR name: Mohamed Al Rawahi, MD role: SUB_INVESTIGATOR name: Adil Al Riyami, MD role: SUB_INVESTIGATOR name: Said Al Hadhrami, MD role: SUB_INVESTIGATOR name: Hatim Al Lawati, MD role: SUB_INVESTIGATOR lat: 23.58413 lon: 58.40778 hasResults: False
nctId: NCT06276114 id: 07 briefTitle: IVL vs ELCA for Stent Underexpantsion (IVL-ELCA DRAGON) acronym: DRAGON overallStatus: COMPLETED date: 2020-08-01 date: 2023-10-31 date: 2023-10-31 date: 2024-02-23 date: 2024-02-23 name: Medical University of Silesia class: OTHER briefSummary: The IVL- ELCA DRAGON Registry is a multicenter study that enrolled consecutive patients with stent underexpansion treated with IVL ora ELCA in high-volume PCI centers.
nctId: NCT06276101 id: NEWISH-HPV-101 briefTitle: NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL overallStatus: RECRUITING date: 2024-01-25 date: 2024-12-30 date: 2025-07-30 date: 2024-02-23 date: 2024-02-23 name: Newish Technology (Beijing) Co., Ltd. class: INDUSTRY briefSummary: This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and tolerability of HPV-16 and HPV-18-targeted DNA plasmid vaccine (NWRD08) in patients HPV-16 and/or HPV-18 related cervical HSIL. conditions: High-grade Squamous Intraepithelial Lesion (HSIL) studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 9 type: ESTIMATED name: NWRD08 administered by electroporation measure: Safety measure: Dose-limiting toxicity (DLT) measure: Immunogenicity measure: Histopathology outcome and HPV Viral clearance measure: The recommended phase II dose (RP2D) sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Peking Union Medical College Hospital status: RECRUITING city: Beijing state: Beijing zip: 100730 country: China name: Fang Jiang, M.D. role: CONTACT phone: 86-010-69155635 email: 13671170943@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06276088 id: NFEC-2024-067 briefTitle: Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy overallStatus: RECRUITING date: 2024-02-18 date: 2025-12-31 date: 2026-10-31 date: 2024-02-23 date: 2024-03-15 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: Immune checkpoint inhibitors have ushered in a new era of cancer treatment, bringing significant survival benefits to patients. However, some patients have accelerated tumor growth in the early stage of immunotherapy, called hyperprogression. The quality of life of patients with hyperprogression is seriously reduced, and there is no effective treatment at present, and the prognosis is extremely poor. Therefore, early identification of high-risk groups of hyperprogression is the key to prevent hyperprogression. However, there are no effective biomarkers to predict hyperprogression. By sequencing, proteomics and metabolomics analysis of clinical tissue and blood samples, we found that the level of SAA1 was significantly increased in patients with hyperprogression, and SAA1 was an effective marker for predicting hyperprogression in pan-cancer. We planned to conduct a multicenter, prospective cohort study to verify the reliability of SAA1 as a marker for predicting hyperprogression of immunotherapy in pan-cancer patients. conditions: Immunotherapy conditions: Hyperprogression conditions: Biomarker studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 374 type: ESTIMATED measure: Incidence of hyperprogression measure: Event-free survival measure: Progression-free survival measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang hospital, Southern medical university status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Jian Guan, M.D. role: CONTACT phone: 86+13632102247 email: guanjian5461@163.com name: Jian Guan, M.D. role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 facility: Fujian Provinical Hospital status: NOT_YET_RECRUITING city: Fuzhou country: China name: Yongmei Dai role: CONTACT lat: 26.06139 lon: 119.30611 facility: Huizhou Central People's Hospital status: NOT_YET_RECRUITING city: Huizhou country: China name: Yunming Tian role: CONTACT lat: 23.11147 lon: 114.41523 facility: Jieyang people's hospital status: NOT_YET_RECRUITING city: Jieyang country: China name: Peibao Lai role: CONTACT lat: 23.5418 lon: 116.36581 facility: Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou status: NOT_YET_RECRUITING city: Meizhou country: China name: Jianda Sun role: CONTACT lat: 24.2886 lon: 116.11767 hasResults: False